Drug Warning: Cymbalta
Generic name: duloxetine hydrochloride (class of drugs known as serotonin and norepinephrine reuptake inhibitors)
Manufactured and marketed by: by Eli Lilly and Company
Purpose: Designed to work by increasing the activity of the chemicals in the brain known as serotonin and norepinephrine. Cymbalta is approved by the FDA for use in the treatment of depression.
Side Effects Reported
- Cymbalta has been linked to reports of liver problems including hepatitis and cholestatic jaundice.
- Cymbalta patients should be mindful of the symptoms of liver damage, which may include, jaundice, dark urine, weakness, nausea, abdominal tenderness near the liver, and flu like symptoms.
- Patients with pre-existing liver problems may be at an increased risk of aggravating their condition and those patients who have substantial alcohol use or suffer from chronic liver disease are advised not to ordinarily be prescribed Cymbalta.
Industry Report
The FDA has recently ordered that all antidepressants, including Cymbalta, must add a "black box warning" to the labeling regarding a possible link to increased suicidal thoughts and behavior in children and adolescents. The black box warning is the strongest warning that the FDA has at its disposal. Data from 24 trials involving 4,400 patients indicated that approximately 2 to 3 percent of children and adolescents that take antidepressants have increased suicidal thoughts and actions.
Seeger Weiss is not currently pursuing lawsuits on this drug, but its drug warnings will remain on our radar.
- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
